Limited Contribution of Creatine Kinase-Myocardial Band Alongside High-Sensitivity Cardiac Troponin in Diagnosing Acute Myocardial Infarction in an Emergency Department
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cardiac biomarkers, especially high-sensitivity cardiac troponin C or I (hs-cTnC or hs-cTnI, respectively), are vital for diagnosing acute myocardial infarction (AMI). Despite the specificity of hs-cTn as a biomarker, the creatine kinase-myocardial band (CK-MB) is commonly used alongside hs-cTn in emergency departments (EDs). We analyzed 23,771 simultaneous hs-cTn (hs-cTnT or hs-cTnI) and CK-MB requests for 17,185 patients in tertiary hospital ED in 2022. The objective of this study was to assess their practical value in diagnosing AMI in real-world settings. Among all 17,185 patients tested, 98.0% underwent hs-cTnT and CK-MB tests, and substantially fewer underwent hs-cTnI testing. We observed concordance between the initial hs-cTn and CK-MB results in 71.3% of patients. Of 131 AMI cases, 57 were positive for both biomarkers, 63 for hs-cTn only, and none for CK-MB alone. CK-MB positivity was often found in the absence of AMI. Discrepancies between the hscTnT and hs-cTnI results occurred in 30.0% of patients. Indiscriminate CK-MB testing for diagnosing AMI in EDs should be reconsidered. Efficient use of CK-MB is important for reducing costs and ensuring optimal patient care.
Abstract
Cardiac biomarkers, especially high-sensitivity cardiac troponin C or I (hs-cTnC or hs-cTnI, respectively), are vital for diagnosing acute myocardial infarction (AMI). Despite the specificity of hs-cTn as a biomarker, the creatine kinase-myocardial band (CK-MB) is commonly used alongside hs-cTn in emergency departments (EDs). We analyzed 23,771 simultaneous hs-cTn (hs-cTnT or hs-cTnI) and CK-MB requests for 17,185 patients in tertiary hospital ED in 2022. The objective of this study was to assess their practical value in diagnosing AMI in real-world settings. Among all 17,185 patients tested, 98.0% underwent hs-cTnT and CK-MB tests, and substantially fewer underwent hs-cTnI testing. We observed concordance between the initial hs-cTn and CK-MB results in 71.3% of patients. Of 131 AMI cases, 57 were positive for both biomarkers, 63 for hs-cTn only, and none for CK-MB alone. CK-MB positivity was often found in the absence of AMI. Discrepancies between the hscTnT and hs-cTnI results occurred in 30.0% of patients. Indiscriminate CK-MB testing for diagnosing AMI in EDs should be reconsidered. Efficient use of CK-MB is important for reducing costs and ensuring optimal patient care.
참고문헌 (13)
- Collet JP, "2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation", Eur Heart J, 42, pp.1289~1367 (2021)
- Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology, Circulation, pp.2014, 130[DOI]
- Wiens EJ, "Routine creatine kinase testing does not provide clinical utility in the emergency department for diagnosis of acute coronary syndromes", BMC Emerg Med, 19, pp.37~ (2019)
- Raza S, "Reducing redundant creatine kinase testing in cardiac injury", BMJ Open Qual, 9, pp.e001182~ (2020)
- Baroni S, "Lack of utility of CK-MB in combination with troponin I for the diagnosis of acute coronary syndrome", Intern Emerg Med, 15, pp.1345~1346 (2020)
- Alvin MD, "Eliminating creatine kinase-myocardial band testing in suspected acute coronary syndrome : A value-based quality improvement", JAMA Intern Med, 177, pp.1508~1512 (2017)
- Le RD, "Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting", Am J Emerg Med, 33, pp.72~75 (2015)
- Giger RD, "Rhabdomyolysis : A noncardiac source of increased circulating concentrations of cardiac troponin T?", J Am Coll Cardiol, 76, pp.2685~2687 (2020)
- Gibbons RJ, "The quantification of infarct size", J Am Coll Cardiol, 44, pp.1533~1542 (2004)
- Wilson G, "Overuse of troponin? A comprehensive evaluation of testing in a large hospital system", J Hosp Med, 12, pp.329~331 (2017)
- Eggers KM, "Differences between high-sensitivity cardiac troponin T and I in stable populations : underlying causes and clinical implications", Clin Chem Lab Med, 61, pp.380~387 (2023)
- Collinson PO, "High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers", Clin Chem Lab Med, 57, pp.623~632 (2019)
- Wang GM, "The combination of creatine kinase-myocardial band isoenzyme and point-of-care cardiac troponin", contemporary cardiac troponin for the early diagnosis of acute myocardial infarction, 2022, pp.13, 163~168